The currently available pharmacological treatments for opioid addiction fall into one of two categories: opioid receptor agonists (i.e., methadone, buprenorphine, and buprenorphine/naloxone combination) and opioid receptor antagonists (i.e., naltrexone). Both psychiatrists and patients prefer opioid receptor agonists, of which Indivior’s Suboxone Film is the most widely prescribed branded agent in this market. However, the misuse and diversion potential associated with these treatments are an ongoing concern. Despite psychiatrists’ overall satisfaction with current therapies, they face a number of challenges treating this population, including very low compliance rates, which, in turn, contribute to high relapse rates among their opioid-addicted patients.
- What are the psychiatrist-reported patient shares of opioid addiction treatments across lines of therapy? Is there a difference between the average time a patient remains on treatment and the physician-recommended treatment duration? What are the reasons for discontinuing treatment?
- What are the drivers and limitations influencing psychiatrists’ opioid addiction treatment decisions? What factors drive switching to and from specific branded drugs (e.g., Suboxone Film [Indivior], Zubsolv [Orexo])?
- How has the use of key opioid addiction therapies changed in the past year, and what changes do psychiatrists expect in their prescribing of these drugs in one year?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 U.S. psychiatrists
Key companies: Indivior, Orexo, BioDelivery Sciences, Alkermes
Key drugs: Suboxone Film, Subutex, Sublocade, Zubsolv, Bunavail, Probuphine, Vivitrol, methadone
Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers of and constraints to treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for changes in treatment approach.
- Physician insight on patients’ persistency and compliance.
- Physician-reported recent/anticipated changes in brand use or treatment approach.